Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical… Read more
Market Cap & Net Worth: Endonovo Therapeutics Inc (ENDV)
Endonovo Therapeutics Inc (PINK:ENDV) has a market capitalization of $289.14K ($289.14K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #42248 globally and #13683 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Endonovo Therapeutics Inc's stock price $0.00 by its total outstanding shares 1445713313 (1.45 Billion).
Endonovo Therapeutics Inc Market Cap History: 2015 to 2025
Endonovo Therapeutics Inc's market capitalization history from 2015 to 2025. Data shows change from $520.60 Billion to $289.14K (-74.40% CAGR).
Endonovo Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Endonovo Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
100.77x
Endonovo Therapeutics Inc's market cap is 100.77 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $520.60 Billion | $4.26K | -$5.08 Million | 122063625.79x | N/A |
| 2018 | $26.31 Billion | $83.26K | -$6.44 Million | 316010.50x | N/A |
| 2019 | $2.75 Billion | $310.16K | -$17.31 Million | 8856.14x | N/A |
| 2020 | $29.06 Million | $165.80K | -$395.58K | 175.27x | N/A |
| 2021 | $22.55 Million | $73.11K | -$3.10 Million | 308.50x | N/A |
| 2022 | $26.02 Million | $135.35K | -$18.47 Million | 192.26x | N/A |
| 2023 | $12.58 Million | $140.24K | $6.92 Million | 89.69x | 1.82x |
| 2024 | $1.01 Million | $10.04K | -$2.80 Million | 100.77x | N/A |
Competitor Companies of ENDV by Market Capitalization
Companies near Endonovo Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Endonovo Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Endonovo Therapeutics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Endonovo Therapeutics Inc's market cap moved from $520.60 Billion to $ 289.14K, with a yearly change of -74.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $289.14K | -71.43% |
| 2024 | $1.01 Million | -91.95% |
| 2023 | $12.58 Million | -51.67% |
| 2022 | $26.02 Million | +15.38% |
| 2021 | $22.55 Million | -22.39% |
| 2020 | $29.06 Million | -98.94% |
| 2019 | $2.75 Billion | -89.56% |
| 2018 | $26.31 Billion | -68.62% |
| 2017 | $83.85 Billion | +16.23% |
| 2016 | $72.14 Billion | -86.14% |
| 2015 | $520.60 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Endonovo Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $289.14K USD |
| MoneyControl | $289.14K USD |
| MarketWatch | $289.14K USD |
| marketcap.company | $289.14K USD |
| Reuters | $289.14K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.